CN115469041B - One-measurement-multiple-evaluation content determination method for nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation - Google Patents
One-measurement-multiple-evaluation content determination method for nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation Download PDFInfo
- Publication number
- CN115469041B CN115469041B CN202210959343.5A CN202210959343A CN115469041B CN 115469041 B CN115469041 B CN 115469041B CN 202210959343 A CN202210959343 A CN 202210959343A CN 115469041 B CN115469041 B CN 115469041B
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- chinese medicine
- traditional chinese
- ingredient blood
- replenishing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 79
- 239000004615 ingredient Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000011156 evaluation Methods 0.000 title claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 27
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 claims abstract description 6
- 150000002500 ions Chemical class 0.000 claims description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 30
- 239000013558 reference substance Substances 0.000 claims description 22
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 claims description 18
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 14
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 14
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 claims description 14
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 claims description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 13
- 239000012488 sample solution Substances 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 7
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims description 7
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 7
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 7
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 7
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 7
- 239000004378 Glycyrrhizin Substances 0.000 claims description 7
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims description 7
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 7
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims description 7
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims description 7
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims description 7
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 7
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 7
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims description 7
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 7
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 7
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 7
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 7
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 7
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 7
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 7
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 7
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 7
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 7
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 7
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims description 7
- 229960001587 hesperetin Drugs 0.000 claims description 7
- 235000010209 hesperetin Nutrition 0.000 claims description 7
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 7
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 7
- 229940025878 hesperidin Drugs 0.000 claims description 7
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims description 7
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 7
- 229930019673 naringin Natural products 0.000 claims description 7
- 229940052490 naringin Drugs 0.000 claims description 7
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 7
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims description 7
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 7
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 claims description 6
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000001819 mass spectrum Methods 0.000 claims description 6
- 239000011550 stock solution Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- YBZZAVZIVCBPDJ-UHFFFAOYSA-N schizandrin B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)(O)CC2=CC2=C1OCO2 YBZZAVZIVCBPDJ-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000132 electrospray ionisation Methods 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000005526 G1 to G0 transition Effects 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 10
- 238000003908 quality control method Methods 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 238000012360 testing method Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 241000382455 Angelica sinensis Species 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a one-measurement-multi-evaluation content determination method for a nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation, which adopts a UPLC-MS/MS method to simultaneously determine the content of 16 chemical components in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation. The method can rapidly and effectively measure the contents of 16 components in the nine-ingredient blood-replenishing oral liquid, has high sensitivity, good specificity and reproducibility, and accurate and reliable detection results, and provides an effective method for improving the quality control technical level and the sound quality control system of the nine-ingredient blood-replenishing oral liquid, thereby ensuring the quality uniformity, stability, clinical curative effect and safety of the nine-ingredient blood-replenishing oral liquid.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine quality control, and relates to a one-measurement-multiple-evaluation content determination method for a nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation.
Background
The nine-ingredient blood-replenishing oral liquid is composed of 9 medicinal materials such as ginseng, astragalus root, gynostemma pentaphylla and the like, has the effects of replenishing qi and blood, strengthening spleen and replenishing stomach, and has good effects of replenishing qi and blood and promoting sleep, and is used for treating insomnia and amnesia caused by deficiency of both qi and blood, palpitation and secondary, dizziness, listlessness, short qi and spontaneous perspiration, anorexia and the like. The invention discloses a preparation method and application of a traditional Chinese medicine preparation, and discloses publication number CN1883593A, and the invention name of the nine-ingredient blood-replenishing oral liquid.
The basic research of the nine-ingredient blood-replenishing oral liquid is relatively less, and the existing quality standard
[ YBZ00362007-2015Z ] and literature receiving or reporting thin-layer identification of medicinal materials such as angelica sinensis, liquorice, dried orange peel, ginseng, gynostemma pentaphylla, astragalus membranaceus, schisandra chinensis and the like, and content measurement of ferulic acid in angelica sinensis, schisandra chinensis methyl and astragaloside in astragalus membranaceus, wherein the quality control method of the components is relatively single, and lacks systematicness and comprehensiveness. Therefore, the research and development of the material basis of the nine-ingredient blood-replenishing oral liquid are in progress, and a content measuring method for simultaneously measuring various active ingredients in the nine-ingredient blood-replenishing oral liquid is imperative as a quality control means. The invention researches and establishes and verifies a method for simultaneously measuring the contents of various components in the nine-ingredient blood-replenishing oral liquid based on an ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS/MS) technology, and the method is quick, accurate, high in sensitivity, strong in specificity and good in reproducibility, provides a reliable technology for establishing a perfect quality control technology and a quality control system of the whole production process, improves the quality control level of the nine-ingredient blood-replenishing oral liquid, and ensures the quality and clinical curative effect of the product.
Disclosure of Invention
The invention aims to provide a one-measurement-multiple-evaluation content measuring method for a nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation, which is a measuring method for simultaneously measuring the contents of various ingredients in a nine-ingredient blood-replenishing oral liquid of a traditional Chinese medicine compound preparation for replenishing qi and replenishing blood and promoting sleep based on an ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) technology, and establishes a content measuring method capable of simultaneously measuring 16 main ingredients in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation so as to improve the quality control level of the nine-ingredient blood-replenishing oral liquid.
In order to achieve the purpose of the invention, the invention adopts the following technical proposal and steps:
a method for measuring the content of one or more evaluation components of a nine-ingredient blood-replenishing oral liquid Chinese medicinal preparation adopts a UPLC-MS/MS method, and simultaneously measures the content of 16 chemical components in the nine-ingredient blood-replenishing oral liquid Chinese medicinal preparation;
(1) Establishing standard curves of 16 chemical components;
(2) Obtaining a multi-reaction ion chromatogram of 16 chemical components in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation, precisely sucking 1ml of the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation, placing in a 20ml volumetric flask, adding methanol, carrying out ultrasonic dissolution, fixing the volume to a scale, shaking uniformly, filtering by a filter membrane, and taking a subsequent filtrate as a sample solution;
under the same chromatographic conditions and mass spectrum conditions as in the step (1), the sample solution is injected into a liquid chromatograph-mass spectrometer to obtain a multi-reaction ion chromatogram of each chemical component in the compound preparation;
(3) Determination of 16 chemical component contents in nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation
And determining the content of each chemical component in the compound preparation according to the peak area of the multi-reaction ion chromatogram of each chemical component in the nine-component blood-replenishing oral liquid traditional Chinese medicine preparation and the standard curve of the corresponding chemical component.
The 16 chemical components comprise: ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rd, astragaloside IV, calycosin, hesperidin, naringin, hesperetin, nobiletin, schizandrin A, schizandrin B, schizandrin A, Z-ligustilide, glycyrrhizin, and ammonium glycyrrhizinate.
The step (1) of establishing a standard curve of 16 chemical components is as follows: respectively precisely weighing reference substances such as ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rd, astragaloside IV, calycosin, hesperidin, naringin, hesperetin, nobiletin, schizandrin A, schizandrin B, schizandrin A, ligustilide, glycyrrhizin and ammonium glycyrrhizinate, dissolving with 95% methanol to obtain reference substance stock solutions with certain concentration; precisely sucking 16 reference substance stock solutions respectively, and diluting with 95% methanol to obtain a series of reference substance mixed solutions of 16 chemical components with different concentrations; under the set chromatographic conditions and mass spectrum conditions, respectively injecting the mixed solutions of the reference substances with various concentrations into a liquid chromatograph-mass spectrometer to obtain multi-reaction ion chromatograms of the reference substances with different concentrations; and (3) taking the chromatographic peak area of each reference substance as an ordinate and the concentration of each reference substance as an abscissa, and obtaining the standard curve of each chemical component through linear regression operation.
The chromatographic conditions set are: the chromatographic column adopts a stationary phase of octadecylsilane chemically bonded silica gel; mobile phase: phase A is 0.1% formic acid or water, phase B is acetonitrile; gradient elution; column temperature: 30 ℃; flow rate: 0.3mL/min; sample injection amount: 1 μl;
the elution procedure was: 0-5min,2% B;5-30min,2% -80% B;30-35min,80% -95% B.
The set mass spectrum conditions include:
ionization mode: electrospray ionization; a multi-reaction ion monitoring mode, a full scanning mode; ion spray voltage: -4500V or 5500V; ion source pressure: 15psi; air curtain air pressure: 20psi; drying gas and atomizing gas: nitrogen gas.
Mass spectrometry conditions and ion modes are as follows:
in one embodiment of the present invention, the concentration of each control at S/n=3 and S/n=10 is used as the lowest detection limit and the lowest quantification limit, respectively.
The invention adopts UPLC-MS/MS method to measure the content of 16 chemical components in the nine-ingredient blood-replenishing oral liquid, has the characteristics of high sensitivity, strong reliability, high efficiency and rapidness, and can more effectively control the quality of the nine-ingredient blood-replenishing oral liquid by measuring the content of 16 chemical components in the nine-ingredient blood-replenishing oral liquid, thereby ensuring the clinical curative effect of the nine-ingredient blood-replenishing oral liquid.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 is a multi-reaction ion chromatogram of ligustilide in a control at a certain concentration;
FIG. 2 is a multi-reactive ion chromatogram of calycosin at a concentration in a control;
FIG. 3 is a multi-reactive ion chromatogram of hesperetin at a certain concentration in a control;
FIG. 4 is a multi-reaction ion chromatogram of nobiletin in a control at a certain concentration;
FIG. 5 is a multi-reaction ion chromatogram of schisandrin A in a control at a certain concentration;
FIG. 6 is a multi-reaction ion chromatogram of schisandrin A in a control at a certain concentration;
FIG. 7 is a multi-reaction ion chromatogram of schisandrin B in a control at a certain concentration;
FIG. 8 is a multi-reaction ion chromatogram of astragaloside IV in a control at a certain concentration;
FIG. 9 is a multi-reaction ion chromatogram of glycyrrhizin at a given concentration in the control;
FIG. 10 is a multi-reactive ion chromatogram of naringin at a concentration in a control;
FIG. 11 is a multi-reactive ion chromatogram of hesperidin at a certain concentration in a control;
FIG. 12 is a multi-reactive ion chromatogram of ammonium glycyrrhetate in a control at a concentration;
FIG. 13 is a multi-reaction ion chromatogram of ginsenoside Rg1 in a control at a certain concentration;
FIG. 14 is a multi-reaction ion chromatogram of ginsenoside Re at a certain concentration in the reference;
FIG. 15 is a multi-reaction ion chromatogram of ginsenoside Rd at a certain concentration in the control;
FIG. 16 is a multi-reaction ion chromatogram of ginsenoside Rb1 in a control at a certain concentration;
FIG. 17 is a multi-reaction ion chromatogram of ligustilide in a test sample of the nine-ingredient blood-replenishing oral liquid at a certain concentration;
FIG. 18 is a multi-reaction ion chromatogram of calycosin at a given concentration in a test sample of a nine-ingredient blood-replenishing oral liquid;
FIG. 19 is a multi-reactive ion chromatogram of hesperetin at a certain concentration in a test sample of the nine-ingredient blood replenishing oral liquid;
FIG. 20 is a multi-reaction ion chromatogram of nobiletin in a nine-ingredient blood replenishing oral liquid test sample at a certain concentration;
FIG. 21 is a multi-reaction ion chromatogram of schisandrin A in a certain concentration in a test sample of the nine-ingredient blood replenishing oral liquid;
FIG. 22 is a multi-reaction ion chromatogram of schisandrin A in a test sample of the nine-ingredient blood-replenishing oral liquid;
FIG. 23 is a multi-reaction ion chromatogram of schisandrin B in a certain concentration in a nine-ingredient blood replenishing oral liquid test sample;
FIG. 24 is a multi-reaction ion chromatogram of astragaloside IV in a nine-ingredient blood-replenishing oral liquid test sample at a certain concentration;
FIG. 25 is a multi-reactive ion chromatogram of glycyrrhizin in a test sample of the nine-ingredient blood-replenishing oral liquid at a certain concentration;
FIG. 26 is a multi-reactive ion chromatogram of naringin at a concentration in a test sample of a nine-ingredient blood-replenishing oral liquid;
FIG. 27 is a multi-reactive ion chromatogram of hesperidin at a certain concentration in a test sample of the Jiuwei blood replenishing oral liquid;
FIG. 28 is a multi-reaction ion chromatogram of ammonium glycyrrhizate in a nine-ingredient blood-replenishing oral liquid test sample at a certain concentration;
FIG. 29 is a multi-reaction ion chromatogram of ginsenoside Rg1 in a nine-ingredient blood replenishing oral liquid test sample at a certain concentration;
FIG. 30 is a multi-reaction ion chromatogram of ginsenoside Re in a nine-ingredient blood replenishing oral liquid test sample at a certain concentration;
FIG. 31 is a multi-reaction ion chromatogram of ginsenoside Rd at a certain concentration in a test sample of the nine-ingredient blood-replenishing oral liquid;
fig. 32 is a multi-reaction ion chromatogram of ginsenoside Rb1 in a test sample of the Jiuwei blood replenishing oral liquid at a certain concentration.
Detailed Description
The advantages and the spirit of the present invention will be better understood by reference to the following examples, which are not intended to limit the invention.
The following are relevant test instruments, standards, reagents and samples used in the examples:
experimental instrument:
an ultra-high performance rapid liquid chromatography system (ExionLC AD) comprising an on-line vacuum degasser, a binary pump, an automatic sampler and a column incubator (Shimadzu);
sciex triple quaternary tandem mass spectrometry detector (SCIEX QTRAP Triple Quad 5500+), containing electrospray ion source (ESI source), analysis software (Sciex, USA);
chromatographic column: waters ACQUITY UPLC HSS T3 (2.1 mm. Times.100 mm,1.8 μm) (Waters, america).
Milli-Q deionized water System (Millipore, U.S.A.); KQ-500DB type numerical control ultrasonic cleaner.
Control: ginsenoside Rg1 (lot number: 110703-202034), ginsenoside Re (lot number: 110754-202129), ginsenoside Rb1 (lot number: 110704-202028), astragaloside IV (lot number: 110781-202118), schizandrin A (lot number: 110857-201815), ligustilide (lot number: 111737-201910) are all purchased from Chinese food and drug assay institute; ginsenoside Rd (lot number: 5826), hesperidin (lot number: 5836), naringin (lot number: 10668), glycyrrhizin (lot number: 9654), ammonium glycyrrhizinate (lot number: 10845), hesperetin (lot number: 10027), nobiletin (lot number: 6082), schizandrin (lot number: 8366), calycosin (lot number: 10659), and schizandrin A (lot number: 7954) were all purchased from Shanghai Shimadder standard technical services Co.
HPLC grade acetonitrile, HPLC grade methanol, HPLC grade formic acid (Fisher, usa); deionized water;
nine-ingredient blood replenishing oral liquid sample: 6 different batches of nine-ingredient blood-replenishing oral liquid are produced by Yingkang pharmaceutical industry Co., ltd.
Example 1 the establishment of a method for simultaneously measuring the contents of various components in a nine-ingredient blood-replenishing oral liquid based on UPLC-MS technology.
1. Preparation of test solutions
Precisely sucking 1ml of the product, placing in a 20ml volumetric flask, adding appropriate amount of methanol, ultrasonic dissolving, fixing volume to scale, shaking, filtering with a filter membrane, and collecting the filtrate as sample solution.
The invention discloses a method for preparing a nine-ingredient blood replenishing oral liquid, which comprises the steps of qualitatively researching main components in a nine-ingredient blood replenishing oral liquid sample solution by adopting ACQUITY I-CLASS Plus ultra-high performance liquid chromatography-XeFo G2-XS four-pole time-of-flight mass spectrum (Waters company in the United states), and totally separating 136 compounds mainly comprising saponins, lignans, flavonoids, phthalides, terpenes, organic acids and other compounds.
2. Carrying out UPLC-MS detection analysis on the nine blood replenishing oral liquid sample solution:
chromatographic conditions: the ExionLC AD ultra-high performance rapid liquid chromatography system comprises a chromatographic column which is HSS T3 (2.1 mm ×100mm,1.8 μm), a column temperature of 30 ℃, a flow rate of 0.3mL/min, a sample injection volume of 1 μL, a mobile phase A which is 0.1% formic acid (positive ion mode) or water (negative ion mode), a mobile phase B which is acetonitrile, and gradient elution conditions: 0-5min,2% B;5-30min,2% -80% B;30-35min,80% -95%.
Mass spectrometry conditions: sciex triple quaternary tandem mass spectrometry detector, analysis software (Sciex, USA); ionization mode: electrospray ionization; a multi-reaction ion monitoring mode, a full scanning mode; ion spray voltage: -4500V or 5500V; ion source pressure: 15psi; air curtain air pressure: 20psi; drying gas and atomizing gas: nitrogen gas. The cleavage process of a compound from a parent ion to a specific daughter ion is monitored quantitatively using a Multiplex Reaction Monitoring (MRM) mode.
The optimized MRM conditions are shown in Table 1.
Table 1: MRM parameters of 16 compounds in nine-ingredient blood-replenishing oral liquid
TABLE 1
3. Methodology investigation
(1) Standard curve, quantitative limit and detection limit
And respectively precisely sucking the mixed stock solution of the reference substances, diluting the mixed stock solution into a series of mixed reference substance solutions (n=6) with concentration gradients by using 95% methanol, and carrying out 1 mu L analysis on each concentration of the reference substances to obtain multi-reaction ion chromatograms of the reference substances at different concentrations, and carrying out linear regression on the concentrations by using chromatographic peak areas of the reference substances to obtain standard curves of the components.
The mixed control solutions were diluted stepwise, and the concentrations of the controls at S/n=3 and S/n=10 were used as the detection Limit (LOD) and the quantification Limit (LOQ), respectively. The results are shown in Table 2, and the experimental results show that the linear correlation coefficient of each compound is good, and the quantitative limit and the detection limit meet the detection requirements.
TABLE 2 Standard Curve, linear Range, detection Limit and quantitative Limit of 16 Compounds in nine-ingredient blood replenishing oral liquid
(2) Precision, repeatability, stability
Precisely transferring 1ml of the nine-ingredient blood replenishing oral liquid, placing in a 20ml volumetric flask, adding a proper amount of methanol, performing ultrasonic dissolution, fixing the volume to a scale, shaking uniformly, filtering with a filter membrane, and taking the subsequent filtrate as a sample solution. Repeating sample injection for 6 times according to the chromatographic conditions, measuring the concentration of each component, and calculating the RSD value of the component to examine the precision of the instrument.
Precisely transferring 1ml of the nine-ingredient blood replenishing oral liquid, placing in a 20ml volumetric flask, adding a proper amount of methanol, performing ultrasonic dissolution, fixing the volume to a scale, shaking uniformly, filtering with a filter membrane, and taking the subsequent filtrate as a sample solution. 6 parts of the sample are prepared in parallel, the concentration of each component is measured by sampling according to the chromatographic conditions, and the RSD value of each component is calculated to investigate the repeatability of the method.
Precisely transferring 1ml of the nine-ingredient blood replenishing oral liquid, placing in a 20ml volumetric flask, adding a proper amount of methanol, performing ultrasonic dissolution, fixing the volume to a scale, shaking uniformly, filtering with a filter membrane, and taking the subsequent filtrate as a sample solution. After the sample is placed at room temperature for 0,3,6, 12 and 24 hours, samples are taken according to the chromatographic conditions, the concentration of each component is measured, and the RSD value of the sample is calculated, so that the stability of the 16 components in the sample solution at room temperature is examined.
The results of the precision, repeatability and stability examination are shown in table 3, and the experimental results show that the results all meet the detection requirements.
(3) Accuracy of
The sample is recovered and measured. Precisely removing 0.5ml of nine-ingredient blood replenishing oral liquid, placing in a 20ml capacity bottle, respectively adding a certain amount of mixed reference substance solution containing 16 ingredients, fixing volume to scale with 95% methanol, shaking, filtering with a filter membrane, and collecting the subsequent filtrate as sample solution. 6 parts of the sample are prepared in parallel, sample injection is carried out according to the chromatographic conditions, the concentration of each component is measured, and the sample injection recovery rate and the RSD value are calculated to investigate the accuracy of the method.
The accuracy inspection results are shown in table 3, and the experimental results show that the method meets the detection requirements.
Table 3 precision, repeatability, stability and accuracy of 16 compounds in nine-ingredient blood replenishing oral liquid
/>
EXAMPLE 2 Simultaneous determination of 16 component contents in nine-ingredient blood-replenishing oral liquid sample
According to the method established in example 1, 6 batches of nine-ingredient blood-replenishing oral liquid were subjected to content measurement. The preparation method of the test solution of the nine-ingredient blood replenishing oral liquid in 6 batches comprises the following steps: precisely transferring 1ml of the nine-ingredient blood replenishing oral liquid, placing in a 20ml volumetric flask, adding a proper amount of methanol, performing ultrasonic dissolution, fixing the volume to a scale, shaking uniformly, filtering with a filter membrane, and taking the subsequent filtrate as a sample solution. 1. Mu.L of each sample was introduced under the above chromatographic conditions, the peak area of the measured component was recorded, the content (CA,. Mu.g/mL) was calculated by substituting the peak area into a standard curve, and the content of the compound in the nine-ingredient blood-replenishing oral liquid was calculated from CA X20, and the results are shown in Table 4.
Table 4 6 the contents of 16 Compounds (μg/mL) in nine-ingredient blood-replenishing oral liquid samples
/>
In conclusion, the method for simultaneously measuring the contents of various components in the nine-ingredient blood-replenishing oral liquid based on the UPLC-MS/MS technology has good precision, repeatability and accuracy; the technical scheme of the invention has feasibility and advancement. The determination method of the invention can further improve the quality control level of the nine-ingredient blood-replenishing oral liquid.
Claims (2)
1. A method for measuring the one-measurement-multiple-evaluation content of a nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation is characterized in that a UPLC-MS/MS method is adopted, and the content of 16 chemical components in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation is measured simultaneously;
(1) Establishing standard curves of 16 chemical components;
(2) Obtaining a multi-reaction ion chromatogram of 16 chemical components in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation, precisely sucking 1ml of the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation, placing in a 20ml volumetric flask, adding methanol, carrying out ultrasonic dissolution, fixing the volume to a scale, shaking uniformly, filtering by a filter membrane, and taking a subsequent filtrate as a sample solution;
under the same chromatographic conditions and mass spectrum conditions as those in the step (1), the sample solution is injected into a liquid chromatograph-mass spectrometer to obtain a multi-reaction ion chromatogram of each chemical component in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation;
(3) Determining the content of 16 chemical components in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation;
determining the content of each chemical component in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation according to the peak area of the multi-reaction ion chromatogram of each chemical component in the nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation and the standard curve of the corresponding chemical component;
the 16 chemical components comprise: ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rd, astragaloside IV, calycosin, hesperidin, naringin, hesperetin, nobiletin, schizandrin A, schizandrin B, schizandrin A, Z-ligustilide, glycyrrhizin, ammonium glycyrrhizinate;
the chromatographic conditions set are: the chromatographic column adopts a stationary phase of octadecylsilane chemically bonded silica gel; mobile phase: phase A is 0.1% formic acid or water, phase B is acetonitrile; gradient elution; column temperature: 30 ℃; flow rate: 0.3mL/min; sample injection amount: 1 μl;
the elution procedure was: 0-5min,2% B;5-30min,2% -80% B;30-35min,80% -95% B;
the set mass spectrum conditions include:
ionization mode: electrospray ionization; a multi-reaction ion monitoring mode, a full scanning mode; ion spray voltage: -4500V or 5500V; ion source pressure: 15psi; air curtain air pressure: 20psi; drying gas and atomizing gas: nitrogen gas;
mass spectrometry conditions and ion modes are as follows:
。
2. the method of claim 1, wherein the step of establishing a standard curve of 16 chemical components in step (1) is: precisely weighing reference substances of ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rd, astragaloside IV, calycosin, hesperidin, naringin, hesperetin, nobiletin, schizandrin A, schizandrin B, schizandrin A, ligustilide, glycyrrhizin and ammonium glycyrrhizinate respectively, dissolving with 95% methanol to obtain reference substance stock solutions with certain concentration; precisely sucking 16 reference substance stock solutions respectively, and diluting with 95% methanol to obtain a series of reference substance mixed solutions of 16 chemical components with different concentrations; under the set chromatographic conditions and mass spectrum conditions, respectively injecting the reference substance mixed solution with each concentration into a liquid chromatography-mass spectrometer to obtain multi-reaction ion chromatograms of the reference substances under different concentrations; and (3) taking the chromatographic peak area of each reference substance as an ordinate and the concentration of each reference substance as an abscissa, and obtaining the standard curve of each chemical component through linear regression operation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210959343.5A CN115469041B (en) | 2022-08-10 | 2022-08-10 | One-measurement-multiple-evaluation content determination method for nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210959343.5A CN115469041B (en) | 2022-08-10 | 2022-08-10 | One-measurement-multiple-evaluation content determination method for nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115469041A CN115469041A (en) | 2022-12-13 |
CN115469041B true CN115469041B (en) | 2023-09-29 |
Family
ID=84366738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210959343.5A Active CN115469041B (en) | 2022-08-10 | 2022-08-10 | One-measurement-multiple-evaluation content determination method for nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115469041B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015614A (en) * | 2007-02-09 | 2007-08-15 | 广西盈康药业有限责任公司 | Quality controlling means of Jiuwei hematopoietic oral liquid |
CN106526002A (en) * | 2016-10-12 | 2017-03-22 | 浙江工业大学 | Method for measuring content of Shenqi blood sugar reducing preparation and application thereof in overall quality control |
CN108498457A (en) * | 2018-04-02 | 2018-09-07 | 青岛科技大学 | One kind having high stability Astragaloside IV soluble type compound and preparation method thereof |
-
2022
- 2022-08-10 CN CN202210959343.5A patent/CN115469041B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015614A (en) * | 2007-02-09 | 2007-08-15 | 广西盈康药业有限责任公司 | Quality controlling means of Jiuwei hematopoietic oral liquid |
CN106526002A (en) * | 2016-10-12 | 2017-03-22 | 浙江工业大学 | Method for measuring content of Shenqi blood sugar reducing preparation and application thereof in overall quality control |
CN108498457A (en) * | 2018-04-02 | 2018-09-07 | 青岛科技大学 | One kind having high stability Astragaloside IV soluble type compound and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
九味补血口服液质量标准研究;黄若干;裴泽建;黄平权;蓝晓东;覃佩莉;梁杰敏;林海英;王小红;;中国民族民间医药(第23期);第16-19页 * |
有助于改善睡眠的中药类保健食品与药膳研究进展;詹皓;吴峰;陈良恩;葛华;张清俊;赵安东;;中国疗养医学(第11期);第1127-1131页 * |
超高效液相串联质谱检测茶叶及茶饮料中咖啡因含量;秦园;王惠芳;吴建兵;钱志荣;吴梅;陈祝军;;食品工业科技(第10期);第286-289、301页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115469041A (en) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109324126B (en) | Method for simultaneously determining 9 chemical components in spina date seeds by using UPLC-MS/MS | |
CN106290659A (en) | Dispensed food for baby Pesticides and the Ultra Performance Liquid Chromatography level Four bar electrostatic field orbit ion trap mass spectrum screening method of veterinary drug | |
CN106814150B (en) | Isotope dilution ultra-performance liquid chromatography-mass spectrometry combined vitamin K determination method1Method (2) | |
CN110849983A (en) | Quantitative analysis method for twelve components of astragalus mongholicus Jianzhong pills in rat plasma | |
CN111579685A (en) | Kit for detecting anticoagulant drugs in blood plasma and application thereof | |
CN107941950B (en) | Method for simultaneously determining nine functional components in different parts of Changshan grapefruit by ultra-high performance liquid chromatography-tandem mass spectrometry | |
WO2024007532A1 (en) | Method for determining dissolution rates of eight representative components in daochi pills | |
CN114674958B (en) | Method for measuring content of active ingredients in fructus gleditsiae | |
CN115876908A (en) | Method for simultaneously determining contents of 24 components in red-blood-guiding pill | |
CN111595983B (en) | Method for measuring chemical component content in veratrum nigrum | |
CN115469041B (en) | One-measurement-multiple-evaluation content determination method for nine-ingredient blood-replenishing oral liquid traditional Chinese medicine preparation | |
CN113075325A (en) | Method for simultaneously measuring contents of 8 index components in Miao medicine radix cynanchi wilfordii | |
CN110243969B (en) | HPLC method for simultaneously determining 7 organic acids in Arisaema tuber | |
CN111812219A (en) | Method for detecting concentration of anticoagulant drug in blood plasma | |
CN114113403B (en) | Method for determining liquid chromatography-mass spectrometry (LC-MS) of Hedan tablets | |
CN113866306B (en) | HPLC (high Performance liquid chromatography) characteristic spectrum detection method of pharmaceutical preparation | |
CN114577931B (en) | Solid phase extraction-ultra-high performance liquid chromatography-tandem mass spectrometry rapid determination method for antibiotics in sewage | |
CN111537653B (en) | Method for determining chemical component content in chrysanthemum | |
CN111398505B (en) | Method for simultaneously detecting contents of five components of traditional Chinese medicine for treating infantile enuresis | |
CN111551662B (en) | Quality detection method of angelica sinensis blood-enriching soup | |
Zheng et al. | Simultaneous determination of 14 components in Shuanghua Baihe tablets by ultrasonic-assisted extraction and HPLC-MS/MS | |
CN109324139A (en) | Ribosylzeatin liquid-liquid extraction-liquid chromatography-tandem mass spectrometry measuring method in a kind of tobacco leaf | |
CN110057938A (en) | 7 enter the method for measurement of concentration of blood component in a kind of eucommia ulmoides extracts | |
CN118225947A (en) | Method for detecting nonsteroidal impurity components in natural source conjugated estrogens | |
CN114487179B (en) | Adulteration detection method for ophiopogon japonicus in Tianwang heart tonifying pill |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |